Berenberg Bank set a €108.00 ($125.58) target price on MorphoSys (ETR:MOR) in a research note released on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on MorphoSys and gave the stock a buy rating in a research report on Thursday, April 4th. Deutsche Bank set a €125.00 ($145.35) price target on MorphoSys and gave the stock a buy rating in a research report on Friday, April 26th. Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys and gave the stock a neutral rating in a research report on Tuesday. Finally, Independent Research set a €96.00 ($111.63) price objective on MorphoSys and gave the company a neutral rating in a research report on Thursday, May 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. MorphoSys presently has a consensus rating of Hold and a consensus price target of €100.78 ($117.18).
Shares of MOR opened at €88.05 ($102.38) on Tuesday. The company has a current ratio of 7.75, a quick ratio of 7.53 and a debt-to-equity ratio of 8.65. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €124.90 ($145.23). The company has a market capitalization of $2.78 billion and a PE ratio of -47.39.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.